Will Breakthrough Therapies Face Reimbursement Challenges?
Executive Summary
After an Aetna official suggests there may be reimbursement uncertainty for products developed under the new expedited regulatory pathway, CDER Director Woodcock defends FDA’s review process and says such drugs are expected to be robustly more effective than existing treatments.